CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
ID: 347053Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347053

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21), aimed at developing medical countermeasures (MCMs) to address serious health risks from chemical threats. This funding opportunity focuses on exploratory research that generates preliminary data essential for the discovery and validation of novel treatment strategies, including the repurposing of FDA-approved products, to combat the effects of toxic chemical exposures resulting from terrorist activities or industrial accidents. The initiative underscores the importance of enhancing national security and public health preparedness against chemical incidents, with a funding ceiling of $275,000 available over a two-year period. Interested applicants must submit their proposals by May 30, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-139-Full-Announcement.html
    PAR-23-139.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), invites applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21). This funding opportunity focuses on developing medical countermeasures (MCMs) targeting serious health risks from chemical threats, which may arise from terrorist activities or industrial accidents. The initiative encourages exploratory research that produces preliminary data essential for further development of candidate MCMs. Eligible applicants include various educational institutions, nonprofits, and local governments, with a budget limit of $275,000 over two years. Applications should address the discovery of new treatment strategies, including repurposing FDA-approved products. Key dates highlight submission deadlines from April 30, 2023, through May 30, 2025. NIAID, NINDS, and other NIH components emphasize the significance of this research for national security and public health preparedness against chemical incidents. The proposal aims to advance knowledge and capability in effectively responding to public health emergencies involving chemical exposures.
    Similar Opportunities
    CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT), aimed at supporting the early-stage development of therapeutics to mitigate health impacts from toxic chemical exposures. This initiative focuses on identifying and validating therapeutic candidates that can address the effects of chemical warfare agents and toxic industrial chemicals, particularly in large-scale public health emergencies. Eligible applicants, including higher education institutions, nonprofits, and tribal governments, can request funding up to $350,000 annually for the UG3 phase and $450,000 for the UH3 phase, with applications due by October 17, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Exploratory/Developmental Research for World Trade Center Health Program Evidence-based Strategies to Improve Treatment Effectiveness, Diagnostic Practices, and Program Evaluation (R21)
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a Notice of Funding Opportunity (NOFO) for exploratory and developmental research (R21) aimed at improving treatment effectiveness and diagnostic practices for health conditions related to the September 11, 2001, terrorist attacks under the World Trade Center (WTC) Health Program. This initiative seeks innovative research addressing uncertainties in diagnosing and treating conditions among WTC responders and survivors, with a focus on health equity for vulnerable populations. The program anticipates awarding between 4 to 8 grants, with an estimated total funding of $4 million available over two years, and applications are due by October 29, 2024. Interested applicants can reach out to James Yiin, PhD, at JYiin@cdc.gov for further information.
    NIOSH Exploratory/Developmental Grant Program (R21)
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering the NIOSH Exploratory/Developmental Grant Program (R21) to support innovative research aimed at understanding and mitigating risks associated with occupational diseases and injuries. This grant program seeks to fund projects that explore methods for reducing workplace hazards and translating scientific findings into effective prevention strategies, thereby addressing the significant burden of occupational health issues. Eligible applicants include a diverse range of entities such as higher education institutions, nonprofits, and various government organizations, with a total funding pool of $1 million available, allowing for awards up to $200,000 per project over a two-year period. Interested parties must submit their applications by November 17, 2024, and can find additional information and application guidelines at the provided link or by contacting the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This grant program aims to support early-stage, high-risk exploratory research focused on developing innovative technologies that address barriers in therapeutic development, rather than targeting specific diseases or clinical trials. The initiative is designed to expedite the discovery and delivery of treatments, diagnostics, and devices to patients by fostering innovative research that can attract industry collaboration and additional funding. Eligible applicants may request up to $275,000 in direct costs over a maximum project period of two years, with applications due by June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.